Neoantigen-Specific TIL in GI Cancers: Prognostic Factors
Feb 28
Probiotic and Low FODMAP
Mar 01
Neoantigen-Specific TIL in GI Cancers: Results
Feb 28
Zongertinib Receives FDA Approval
Mar 02
Neoantigen-Specific TIL in GI Cancers: Patient Population
Feb 28
IBS-Mental Health Genomics
Mar 01
Neoantigen-Specific TIL in GI Cancers: What is TIL Therapy?
Feb 28
OPBC-07/microNAC: Clinical Implications
Feb 24
OPBC-07/microNAC: Key Findings
Feb 24
OPBC-07/microNAC: Study Profile
Feb 24
OPBC-07/microNAC: Primary Objective
Feb 24
SunRISe-4: Safety Profile & Next Steps
Feb 23
OPBC-07/microNAC: Standard Treatment and the Shift Toward Surgical De-Escalation
Feb 24
AV in CLL
Feb 25
SGLT2i & CKD/HF
Feb 23
SunRISe-4: Recurrence-Free Survival
Feb 23
EyeCan Season 6, Episode 6 - When the Body Says Nothing - the Story Behind the Biomaterial Comprising the PRESERFLO® MicroShunt Used to Treat Glaucoma with guest Dr. Leonard Pinchuk